Epizyme, Inc.
PEDIATRIC DOSING FOR TREATMENT OF CANCER WITH AN EZH2 INHIBITOR

Abstract:

The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.